XML 48 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8
Condensed Consolidated Statements of Income and Comprehensive Income (USD $)
In Thousands, except Per Share data, unless otherwise specified
 3 Months Ended
Sep. 30, 2014
Sep. 30, 2013
Molecular diagnostic testing $ 164,507 $ 192,987
Pharmaceutical and clinical services 4,330 9,480
Total revenue 168,837 202,467
Costs and expenses:    
Cost of molecular diagnostic testing 32,797 21,439
Cost of pharmaceutical and clinical services 2,068 4,042
Research and development expense 22,612 16,803
Selling, general, and administrative expense 85,440 77,279
Total costs and expenses 142,917 119,563
Operating income 25,920 82,904
Other income (expense):    
Interest income 55 1,362
Other (98) (439)
Total other income (expense) (43) 923
Income before income taxes 25,877 83,827
Income tax provision 9,895 28,362
Net income 15,982 55,465
Earnings per share:    
Basic $ 0.22 $ 0.70
Diluted $ 0.21 $ 0.68
Weighted average shares outstanding    
Basic 72,763 79,575
Diluted 76,086 81,798
Comprehensive income:    
Net income 15,982 55,465
Unrealized gain (loss) on available-for-sale securities, net of tax (132) 285
Change in foreign currency translation adjustment, net of tax (721) 504
Comprehensive income $ 15,129 $ 56,254